文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

快速开发COVID-19疫苗对疫苗犹豫的影响

Influence of rapid COVID-19 vaccine development on vaccine hesitancy.
PubMed 文献 · Vaccine · 2021-11-13

2020年7月第一周,216名参与者评估三种假设疫苗情景(FDA批准疫苗「下周」「一年后」「两年后」上市),采用多元协方差分析。结果显示下周疫苗感知有效性最低,两年疫苗自我效能高于下周疫苗,下周疫苗感知风险高于一年疫苗;接种意愿组间无差异;疫苗阴谋信念与感知有效性、自我效能、接种意愿负相关,与感知风险正相关。

要点

  • 下周上市疫苗的感知有效性最低(η2p=.045)。
  • 两年疫苗自我效能高于下周疫苗(η2p=.029)。
  • 下周疫苗感知风险高于一年疫苗(η2p=.032)。

核心结论

  • COVID-19疫苗的快速开发可能加剧了公众对有效性、可及性和安全性的担忧,但当前结果显示公众普遍愿意接种即使是最快速开发的疫苗。
  • 仍有必要公开透明地沟通疫苗有效性和安全性,并努力减少疫苗阴谋信念。

研究设计与样本

  • 2020年7月第一周,216名参与者被随机分配评估三种假设疫苗情景之一,分别描述FDA批准的疫苗「下周」「一年后」或「两年后」上市。
  • 因变量为感知疫苗有效性、自我效能、感知疫苗风险和接种意愿;协变量包括疫苗阴谋信念、科学悲观主义、媒体依赖和感知COVID-19风险;数据分析采用多元协方差分析(MANCOVA)。

主要发现

  • 感知疫苗有效性在下周疫苗组最低(η2p=.045)。
  • 自我效能在两年疫苗组高于下周疫苗组(η2p=.029)。
  • 感知疫苗风险在下周疫苗组高于一年疫苗组(η2p=.032)。
  • 接种意愿在实验组间无差异。
  • 疫苗阴谋信念与感知疫苗有效性(η2p=.142)、自我效能(η2p=.031)和接种意愿(η2p=.143)负相关,与感知疫苗风险正相关(η2p=.216)。

临床怎么用

  • 作者认为,仍需公开透明地沟通疫苗有效性和安全性,并努力减少疫苗阴谋信念。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In the race to deploy vaccines to prevent COVID-19, there is a need to understand factors influencing vaccine hesitancy. Secondary risk theory is a useful framework to explain this, accounting for concerns about vaccine efficacy and safety. METHODS: During the first week of July, 2020, participants (N = 216) evaluated one of three different hypothetical vaccine scenarios describing an FDA-approved vaccine becoming available "next week," "in one year," or "in two years." Dependent variables were perceived vaccine efficacy, self-efficacy, perceived vaccine risk, and vaccination willingness. Covariates included vaccine conspiracy beliefs, science pessimism, media dependency, and perceived COVID-19 risk. Data analysis employed multiple analysis of covariance (MANCOVA). RESULTS: Perceived vaccine efficacy was lowest for the next-week vaccine (η2p = .045). Self-efficacy was higher for the two-year vaccine than the next-week vaccine (η2p = .029). Perceived vaccine risk was higher for the next-week vaccine than for the one-year vaccine (η2p = .032). Vaccination willingness did not differ among experimental treatments. In addition, vaccine conspiracy beliefs were negatively related to perceived vaccine efficacy (η2p = .142), self-efficacy (η2p = .031), and vaccination willingness (η2p = .143) and positively related to perceived vaccine risk (η2p = .216). CONCLUSIONS: The rapid development of the COVID-19 vaccine may have heightened public concerns over efficacy, availability, and safety. However, the current findings showed a general willingness to take even the most rapidly developed vaccine. Nonetheless, there remains a need to communicate publicly and transparently about vaccine efficacy and safety and work to reduce vaccine conspiracy beliefs.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rosenthal S, Cummings CL. Influence of rapid COVID-19 vaccine development on vaccine hesitancy. Vaccine. 2021. PMID: 34802786. doi:10.1016/j.vaccine.2021.11.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。